Revolutionizing Healthcare Innovation: The Role of Healthcare Commercialization Programs (HCPs)
In an era of increasingly constrained funding and a pressing need to improve the quality, cost, and access to care, the healthcare industry faces significant challenges in translating promising academic research into practical, cost-effective solutions for patients. While new technologies and innovations hold the key to addressing these issues, the reality in healthcare is a decreasing efficiency in translating research and development (R&D) into practice, a phenomenon sometimes likened to “Eroom’s Law” in the pharmaceutical industry. A major hurdle in this translation journey is the “Valley of Death” – a critical gap between early-stage academic research and successful commercialization. Technologies emerging from academia often fail to attract financially motivated investors because they lack a clear commercialization pathway and a well-articulated value proposition.
Academic investigators, despite their scientific excellence, are frequently unprepared to address commercial considerations like market risk, often prioritizing publishing results over understanding market needs. This leaves institutional technology transfer offices (TTOs) struggling to license technologies with no clear commercial value, and funders with projects that advance no further. Simultaneously, investors are becoming less willing to take on risks they cannot control, such as market acceptance or regulatory hurdles. This has made the Valley of Death “harsher and wider,” requiring robust preparation and de-risking of both technology and market aspects for innovations to succeed.
To bridge this critical gap, Healthcare Commercialization Programs (HCPs) are emerging as a vital option for academic institutions. HCPs are designed to enhance the efficiency and consistency with which academic insights and technologies are translated into viable products and services. They expand the skillset of investigators and boost an institution’s innovation capacity by helping teams translate specific healthcare innovations into practice. These programs build upon the fundamentals of successful initiatives like the National Science Foundation’s Innovation Corps (I-Corps) program, while uniquely adapting to the specific challenges inherent in healthcare.
Effective HCPs address unique issues within healthcare commercialization, including:
- Complex Buying Dynamics: The users and economic buyers of healthcare products or services are often distinct and difficult to identify, with potentially misaligned objectives.
- Intricate Reimbursement Processes: Reimbursement for healthcare solutions is a highly regulated and complex process, unlike pricing in a free market.
- Rigorous Regulatory Pathways: Early decisions can have enormous implications on the time and cost required for product testing and validation, making the “minimally viable product” approach less straightforward than in other industries.
- Professional Culture: Healthcare professionals, due to their extensive training and investment, face high professional and personal risks if they pursue start-ups, yet their continuous engagement is crucial for success.
- High Funding Requirements: Healthcare innovations typically demand substantial investment (e.g., billions for new drugs, tens of millions for medical devices), making it challenging to attract smaller-scale investors.
To navigate these complexities, effective HCPs incorporate distinguishing features such as diverse team composition that includes clinical, technical, and business perspectives, with the business/entrepreneurial lead coordinating efforts. They rely on executive faculty who are healthcare industry experts providing consistent, experienced guidance and feedback to teams. The program content is specifically tailored to cover healthcare’s complex buying dynamics, reimbursement, regulatory aspects, and workflow implications, in addition to general entrepreneurial topics. The pedagogical style fosters frank, objective feedback while also building strong rapport with team members. Critically, HCPs are most effective when leveraged within a broader innovation ecosystem, rather than as standalone activities, ideally as an early “Phase 0” award to efficiently allocate resources towards projects with the highest likelihood of translational success.
Ultimately, HCPs offer a cost-effective strategy for institutions and funders to increase the probability of successful commercialization and patient impact, while simultaneously building the innovation capacity of academic investigators by providing them with crucial “learn-by-doing” entrepreneurial skills.
Reference for the Source:
Collins, J. M., Reizes, O., & Dempsey, M. K. (2016). Healthcare Commercialization Programs: Improving the Efficiency of Translating Healthcare Innovations From Academia Into Practice. Journal of Translational Engineering in Health and Medicine, 7, 1-13. https://doi.org/10.1109/JTEHM.2016.2609915
